We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 10, 2022

Value of Plasma Cell–Depleting Escalation Therapies for Patients With Treatment-Refractory Severe Autoimmune Encephalitis

European Journal of Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Neurology
Clinical characteristics, treatments, outcome, and prognostic factors of severe autoimmune encephalitis in the intensive care unit: Standard treatment and the value of additional plasma cell-depleting escalation therapies for treatment-refractory patients
Eur. J. Neurol. 2022 Sep 29;[EPub Ahead of Print], L Schwarz, N Akbari, H Prüss, A Meisel, F Scheibe

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading